Evidence map›Paper›PMID 38324578›Full record

ArticlePloS one2024

Neutrophil-like cells derived from the HL-60 cell-line as a genetically-tractable model for neutrophil degranulation.

Suhani B Bhakta, Stefan M Lundgren, Bethany N Sesti, Barbara A Flores, Emel Akdogan, Sean R Collins, Frances Mercer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 26 citations in OpenAlex.

  1. CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Frontiers in immunology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. RABEP1 amplifies front signaling in neutrophil migration.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Suhani B BhaktaDepartment of Biological Sciences, California State Polytechnic University Pomona, Pomona, CA, United States of America.
Stefan M LundgrenDepartment of Microbiology and Molecular Genetics, University of California Davis, Davis, CA, United States of America.
Bethany N SestiDepartment of Biological Sciences, California State Polytechnic University Pomona, Pomona, CA, United States of America.
Barbara A FloresDepartment of Biological Sciences, California State Polytechnic University Pomona, Pomona, CA, United States of America.
Emel AkdoganDepartment of Microbiology and Molecular Genetics, University of California Davis, Davis, CA, United States of America.ORCID 0000-0002-0649-6436
Sean R CollinsDepartment of Microbiology and Molecular Genetics, University of California Davis, Davis, CA, United States of America.ORCID 0000-0002-4276-5840
Frances MercerDepartment of Biological Sciences, California State Polytechnic University Pomona, Pomona, CA, United States of America.ORCID 0000-0002-7324-0270
California State Polytechnic University · USUniversity of California, Davis · US

Funding

Rewiring Control of Leukocyte Motility for Therapeutic ApplicationDP2HD094656 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COLLINS, SEAN RYAN · 2017 to 2017
$2.4M
Determining the subcellular and molecular players in neutrophil trogocytic killing of the sexually-transmitted parasite Trichomonas vaginalisSC3GM135046 · NIGMS · CALIFORNIA STATE POLY U POMONA · PI MERCER, FRANCES · 2020 to 2023
$441k
NICHD NIH HHS DP2 HD094656NIGMS NIH HHS SC3 GM135046
6 · The paper itself

Abstract

Research on neutrophil biology has been limited by the short life span and limited genetic manipulability of these cells, driving the need for representative and efficient model cell lines. The promyelocytic cell line HL-60 and its subline PLB-985 can be differentiated into neutrophil-like cells (NLCs) and have been used to study neutrophil functions including chemotaxis, phagocytosis, endocytosis, and degranulation. Compared to neutrophils derived from hematopoietic stem cells, NLCs serve as a cost-effective neutrophil model. NLCs derived from both HL-60 and PLB-985 cells have been shown to perform degranulation, an important neutrophil function. However, no study has directly compared the two lines as models for degranulation including their release of different types of mobilizable organelles. Furthermore, Nutridoma, a commercially available supplement, has recently been shown to improve the chemotaxis, phagocytosis, and oxidative burst abilities of NLCs derived from promyelocytic cells, however it is unknown whether this reagent also improves the degranulation ability of NLCs. Here, we show that NLCs derived from both HL-60 and PLB-985 cells are capable of degranulating, with each showing markers for the release of multiple types of secretory organelles, including primary granules. We also show that differentiating HL-60 cells using Nutridoma does not enhance their degranulation activity over NLCs differentiated using Dimethyl Sulfoxide (DMSO) plus Granulocyte-colony stimulating factor (G-CSF). Finally, we show that promyelocytic cells can be genetically engineered and differentiated using these methods, to yield NLCs with a defect in degranulation. Our results indicate that both cell lines serve as effective models for investigating the mechanisms of neutrophil degranulation, which can advance our understanding of the roles of neutrophils in inflammation and immunity.

Indexed as

NeutrophilsPhagocytosisCell DegranulationCell DifferentiationGranulocyte Precursor CellsHL-60 CellsHumans

Identifiers

PMID38324578
PMCPMC10849234
OpenAlexW4391594721

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.